Biosimilar changes ASP outpacing reimbursement making not affordable to use Working with CMS but needs further legislati
Tweet Content
Biosimilar changes
ASP outpacing reimbursement making not affordable to use
Working with CMS but needs further legislation to fix this
FDA may change interchangeability status for medications to no longer require switching studies
@ACRheumDC @RheumNow #ACR24 https://t.co/daYQJvsHRG
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off